We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.11 | 0.08% | 130.23 | 131.05 | 129.63 | 131.05 | 1,466,791 | 16:43:01 |
From Apr 2019 to Apr 2024
By Colin Kellaher
Samsung Bioepis Co. on Tuesday said the U.S. Food and Drug Administration accepted for review its biologics license application for SB8, a biosimilar to Roche Holdings AG's (ROG.EB) cancer drug Avastin.
The joint venture of Samsung BioLogics Co. (207940.SE) and Biogen Inc. (BIIB) submitted the BLA in September.
Biosimilars are near-copies of biologic drugs, such as Avastin, that are made from living cells and are analogous to generic copies of traditional pill-form medicines.
Samsung Bioepis said SB8, if approved, will be commercialized in the U.S. by Merck & Co. (MRK) under a 2013 collaboration agreement.
Amgen Inc. (AMGN) and Allergan PLC (AGN) in July jointly launched the first biosimilar to Avastin in the U.S., and Pfizer Inc. (PFE) has said it plans to launch its own Avastin biosimilar on Dec. 31.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 19, 2019 08:30 ET (13:30 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
